SAN FRANCISCO, Sept. 28, 2010 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc., a leader in innovative biologics, announced today that Julia P. Gregory, president and chief executive officer, will be presenting at the 9th Annual BIO Investor Forum in San Francisco, California on Wednesday, October 6, 2010 at 1:00 pm Pacific Daylight Time in the Pacific Heights room. Ms. Gregory will present an overview of FivePrime, discuss the company's clinical and preclinical development programs and its recent collaboration with GlaxoSmithKline.
About FivePrime
Five Prime Therapeutics, Inc. is a clinical-stage, privately-held, biotechnology company discovering and developing innovative protein and antibody therapeutics. FivePrime is currently testing FP-1039, a first-in-class biologic, in a Phase I study for patients with solid tumors and a Phase II trial in mutant endometrial cancer will begin soon. Using its world-class biologics discovery platform, FivePrime is building a strong product pipeline in oncology, immunology and metabolic diseases. Its proprietary platform integrates a unique suite of technologies to mine the entire extracellular human proteome – the complete collection of secreted proteins and receptors - for medically relevant therapeutic protein drugs. FivePrime is collaborating with Pfizer, Inc. in the fields of oncology and diabetes and GlaxoSmithKline for skeletal muscle disorders. For more information, visit www.fiveprime.com.
The Five Prime Therapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8029
CONTACT: Five Prime Therapeutics, Inc. Stephanie Andrade 415-365-5719 stephanie.andrade@fiveprime.com
